BRAF and colorectal carcinoma: Nevertheless, the BRAF V600E mutation retained the negative effect on first line PFS (p = 0.003) and OS (p = 0.042) after multivariate survival analysis, which confirmed the high invasiveness and insensitivity to chemotherapy of CRC harboring the BRAF V600E mutation.